Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biotech Co. Opens New Psychedelic Research Facility

Stockhouse Editorial
1 Comment| March 18, 2022

{{labelSign}}  Favorites
{{errorMessage}}


(Image via Biomind Labs Inc.)

The potential of the psychedelics market is estimated to be more than $5 billion (USD) and the expected total estimated market size could be as high as $100 billion … Biomind Labs Inc. (NEO: BMND, Forum) wants a piece ….

The biotech research and development company announced this week that it had opened its new clinical psychedelic research facility in the University Hospital Onofre Lopes, taking a major step for the development of the next generation of pharmaceuticals.

Speaking on this news for investors, Biomind CEO Alejandro Antalich said that with the opening of this new clinical psychedelic research facility, the team continues to distinguish themselves in the global psychedelic landscape, strengthening our pioneering position in three molecules and developing a new kind of contemporary approach for psychedelic treatments.

“The past year and a half has been very intense and focused in terms of clinical research and drug development. This fantastic new facility will play a key role in shaping the future of our proposed commercial clinical trials in the US.”

The company’s Scientific and Clinical Advisor, Dráulio Aráujo added that this new facility and a highly qualified team of scientists further strengthens Biomind’s goal to lead psychedelics to a new frontier of mental health treatment.

“The facility will conduct the first Phase II Clinical Trial using inhaled DMT for treatment-resistant depression under the new model of psychiatric intervention with DMT in conjunction with traditional psychological approaches.”


FULL DISCLOSURE: Biomind Labs Inc. is a client of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today